NET-SMART Therapy: A Targeted Prodrug Strategy (II)
Justin Annes, MD, PhD
Funded Research Projects
Molecular Influences of Racial Disparities in Pancreatic Neuroendocrine Tumors
J. Bart Rose, III, MD, MAS, FACS
Targeted alpha therapy of NETs using somatostatin-based radiopharmaceuticals with improved tumor-to-kidney ratio, the theranostic approach.
Prof. Dr. Apr. Frederik Cleeren
Mesenteric fibrosis in small intestinal neuroendocrine tumors: pathogenesis
Martyn Caplin, DM, FRCP
New models to study neuroendocrine tumors
Patricia Dahia, MD, PhD
uPAR-targeted PRRT: new radionuclide-based therapy
Andreas Kjaer, MD, PhD, DMSc
Epigenetic dysregulation of transposons in pancreatic neuroendocrine tumors
Parijat Senapati, PhD
Digital image analysis in NETs
Michelle Kang Kim, MD, PhD
Discovering new inhibitors of pancreatic NET glucose consumption
Peter M. Clark, PhD
Enhancing somatostatin agonist radionuclide therapy in GEP-NETs
Jeffrey Frost, PhD